Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service decompression & minimally invasive spine cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (250 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 13 | 488 | 40% |
| 2020 | 9 | 240 | 43% |
| 2021 | 10 | 376 | 46% |
Laminotomy, laminectomy, interspinous devices; the MIS call point. Professional codes (what the surgeon bills): CPT 63030, 63047, 63020, 63045, 22867; the hospital bills MS-DRG 518, 519, 520.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Mexico; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 219 | 9,586−3.4%/yr | −3.4%/yr | 2.8 | 7% | 10,100 in 2030+0.8%/yr |
| Arizona | 72 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Lumbar fusion | 8 | 2820%/yr | 0%/yr | 1.20.4× | 0% | 180 in 2030−7.3%/yr |
| Cervical fusion & disc arthroplasty |
Decompression & minimally invasive spine in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
| ≈ 340 |
| – |
| 2026 est. | ≈ 340 | – |
| 2022 | 6 | 323 | 50% |
| 2023 | 6 | 294 | 53% |
| 2024 | 7 | 250 | 54% |
| 2025 from claims | – | 341 275–400 | 54% |
| 2026 forecast | – | 340 266–427 | 55% |
| 2027 forecast | – | 342 254–452 | 55% |
| 2028 forecast | – | 344 244–475 | 56% |
| 2029 forecast | – | 347 236–497 | 56% |
| 2030 forecast | – | 349 228–517 | 56% |
In 2025, 38% inpatient hospital, 62% hospital outpatient.
| 2,815−4.4%/yr |
| −4.4%/yr |
| 3.7 |
| 14% |
| 3,290 in 2030+2.6%/yr |
| Washington | 74 | 2,603−5.2%/yr | −5.2%/yr | 3.3 | 17% | 2,650 in 2030+0.3%/yr |
| Colorado | 51 | 2,105−5.5%/yr | −5.5%/yr | 4.2 | 5% | 2,480 in 2030+2.7%/yr |
| Oregon | 37 | 1,683−5.9%/yr | −5.9%/yr | 3.9 | 38% | 1,690 in 20300%/yr |
| Utah | 31 | 1,279−3.9%/yr | −3.9%/yr | 5.6 | 16% | 1,510 in 2030+2.8%/yr |
| Nevada | 27 | 1,021−8%/yr | −8%/yr | 3.4 | 4% | 1,050 in 2030+0.5%/yr |
| Idaho | 23 | 876−1.5%/yr | −1.5%/yr | 4.2 | 1% | 1,130 in 2030+4.3%/yr |
| Montana | 11 | 616−3.5%/yr | −3.5%/yr | 3.2 | 9% | 590 in 2030−0.8%/yr |
| Alaska | 10 | 340+0.8%/yr | +0.8%/yr | 2.8 | 13% | 430 in 2030+3.8%/yr |
| Wyoming | 9 | 331−4.1%/yr | −4.1%/yr | 3.0 | 10% | 310 in 2030−0.8%/yr |
| Hawaii | 7 | 234−1.1%/yr | −1.1%/yr | 1.8 | 12% | 140 in 2030−8.4%/yr |
| 2 |
| 123−6.5%/yr |
| −6.5%/yr |
| 0.50.4× |
| 0% |
| 250 in 2030+13%/yr |
| Kyphoplasty & vertebroplasty | 1 | 106−5.5%/yr | −5.5%/yr | 0.50.5× | 0% | 90 in 2030−3.6%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Globus Medical leads with 76% of company spending on these surgeons in 2025, +66 pts on 2024.
In 2025, 5 companies reported engagement with New Mexico’s surgeons worth $8,922 in consulting, speaking, meals and travel tied to these products, about $1,275 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.